Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Bousquet, 2020 OBSanticoagulant, prophylactic dosecontrolCOVID 19 hospitalizedNA
-/- suggested
  • suggested 57 % decrease in deaths
Bousquet, 2020 OBSanticoagulant, prophylactic doseanticoagulant, curative doseCOVID 19 hospitalizedNA
-/- inconclusive
    Bousquet, 2020 OBSanticoagulant, curative dosecontrolCOVID 19 hospitalizedNA
    -/- suggested
    • suggested 62 % decrease in deaths
    Paranjpe, 2020 OBSanticoagulantcontrolCOVID 19 hospitalizedcritical
    786/1987 no results
      the primary result seems inconclusive (no p value given, but in-hospital mortality for AC was 22.5% with a median survival of 21 days, compared to 22.8% and median survival of 14 days in control group)

      COVID-19 severe or critically meta-analysis

      Tang, 2020 OBSanticoagulant, prophylactic dosecontrolCOVID-19 severe or criticallyserious
      99/350 inconclusive

        PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
        Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).